A cheaper way to manage Type 2 diabetes has reached India

The Essentials

• Glenmark brings GLIPIQ to India as a semaglutide treatment for Type 2 diabetes available in both vials and pre-filled pens.
• The company currently holds a 1.1 percent share in the Indian diabetes pharmaceutical market and intends to grow this with their latest release.
• Offering the medication in a vial format creates a cheaper pathway for patients starting their long-term treatment journey.

The Pulse

The new diabetes medicine from Glenmark is GLIPIQ, a semaglutide treatment designed to help Indian patients manage Type 2 diabetes more effectively. It arrives in the local market following a comprehensive Phase III clinical study that demonstrated highly favourable safety and efficacy outcomes specifically for the Indian demographic.

The most significant aspect of this release is the format. While most semaglutide treatments are restricted to expensive pre-filled pens, GLIPIQ is also available in traditional vials. This gives doctors the flexibility to adjust doses according to exact patient needs, particularly during the early stages of treatment. It creates a much cheaper pathway for households bearing the cost of long-term care.

Adjusting to injectable medicine often causes anxiety for new patients. To counter this, the company has introduced Sankalp, a dedicated patient support programme. This initiative focuses on helping individuals initiate their therapy smoothly, get comfortable with the physical injection process, and maintain their dosing schedules over the long term.

The Snapshot

The Big Picture

The Indian diabetes management sector is highly competitive, with established players like Sun Pharma and global giants like Novo Nordisk dominating the market. Semaglutide treatments have traditionally been expensive, often pricing out the average household. By offering this medication in a traditional vial format alongside the premium pre-filled pens, Glenmark is directly targeting the cost barrier that prevents many patients from accessing modern therapies. This strategy could force other pharmaceutical companies to rethink their premium-only pricing models for chronic disease treatments in developing markets.

The India Prospective

For Indian households where multiple family members often manage chronic conditions simultaneously, cost dictates treatment choices. Vials are historically cheaper to manufacture and purchase than complex auto-injector pens, keeping monthly pharmacy bills manageable. Furthermore, the Sankalp support programme addresses a common Indian cultural hurdle: the reluctance to self-administer injections at home, ensuring patients do not abandon their prescribed treatment out of fear or confusion.

The Inside Intel

Despite heavy competition, Glenmark’s diabetes division has been significantly outperforming the broader market. Between January and March 2026, their diabetes portfolio recorded a value growth of 11.5 percent. In contrast, the overall Indian pharmaceutical market for diabetes actually contracted by 4.7 percent during the same three-month period, highlighting just how aggressively the company is capturing market share in this specific therapy area.

The UDHQ. Take

Unbox Daily HQ. views this as a highly practical development for families managing chronic care budgets. If your parents have been prescribed semaglutide but the monthly cost of pre-filled pens is straining the household finances, discussing this new vial option with your endocrinologist makes complete sense. The addition of the Sankalp programme also provides much-needed hand-holding for older patients who might be intimidated by needles. It is a pragmatic, cost-sensitive approach to modern diabetes care that directly addresses the reality of out-of-pocket medical expenses in India.

Best for: patients newly prescribed semaglutide who need a cost-effective way to manage their long-term treatment.

Who Is This For: Perfect for 28 to 55 year old working professionals in India managing healthcare decisions and pharmacy bills for their diabetic parents who need affordable treatment options.

The Checkout

Glenmark Pharmaceuticals – India Page

The Source

Glenmark Pharmaceuticals